This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva, Cephalon should lose appeal of EU ‘pay for delay’ fine, court opinion says

( March 27, 2025, 10:16 GMT | Official Statement) -- MLex Summary: The legal challenge lodged by Teva and Cephalon to a fine of 60.5 million euros — which the European Commission imposed on them for agreeing to delay the entry of Teva's generic rival to the sleep-disorder drug Modafinil — should be rejected, according to a court opinion issued today. In his non-binding recommendation for the EU's top court, Advocate General Athanasios Rantos suggested that the appeal be dismissed, saying that an agreement is prohibited, regardless of its effects, where its objective is anticompetitive.The Advocate General opinion is attached. Case reference is C-2/24.  ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections